Placeholder Banner

BIO Comments on FDA Draft Guidance on Multiple Endpoints in Clinical Trials

March 14, 2017

BIO submitted comments on the Food and Drug Administration’s draft guidance, Multiple Endpoints in Clinical Trials.

The draft guidance provides important recommendations for handling major multiplicity problems in clinical trials. However, BIO says the draft guidance fails to address a few important points, including multiplicity adjustments at the interim analysis, multiplicity adjustment on safety endpoints to control the overall false discovery rate of safety signals, elucidation of the calculation methods to be used with the truncated Holm and truncated Hochberg procedures, and basic principles, such as closed test or partition principles, which many of the multiple comparison methods in the guidance are based upon. BIO makes additional recommendations to clarify the guidance.

Download Full Comments Below
BIO Letter MultipleEndpoints FDA-2016-D-4460
Click the link below for full comments
Discover More
We write as a coalition of advocates for the startup ecosystem to voice our strong support for the IGNITE American Innovation Act, legislation to support startups through the economic crisis by allowing companies to monetize tax assets generated…
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the…
July 30, 2020 Re: Docket No. FDA–2019-D-5799: FDA’s Public Meeting, Modernizing the Food and Drug Administration’s Data Strategy. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or…